SavedAdd your journal

Journals / Sağlık Bilimleri Dergisi / 2026 / Cilt: 21 Sayı: 1

Klinik Örneklerden İzole Edilen Staphylococcus Suşlarına Karşı Kinupristin-Dalfopristin, Metisilin ve Vankomisinin in vitro Etkinliğİ

IN VITRO ACTIVITY OF QUINUPRISTIN-DALFOPRISTIN, METHICILLIN AND VANCOMYCIN AGAINST STAPHYLOCOCCUS STRAINS ISOLATED FROM CLINICAL SAMPLES

Erkan Yula(MD.Dept of Med Microbiol, Fac of Med, Mustafa Kemal Un, Hatay)
Turkan TOKA Özer(MD.Dept of Med Microbiol, Fac of Med, Mustafa Kemal Un, Hatay)
Ozcan Deveci(MD.Dept of Med Microbiol, Fac of Med, Mustafa Kemal Un, Hatay)
Alicem Tekin(MD.Dept of Med Microbiol, Fac of Med, Mustafa Kemal Un, Hatay)
Keramettin Yanık(Med Microbiol, Fac of Med, Dicle Un, Diyarbakir)
Suleyman Durmaz(Med Microbiol, Fac of Med, Dicle Un, Diyarbakir)
Pages
45–49
Publication Date
2012-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consequently we think that quinupristin-dalfopristin combination may be an alternative option for treatment of resistant Gram-positive cocci infections like vancomycin

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of the study is to investigate susceptibility of staphylococci strains isolated from various clinical samples to quinupristin-dalfopristin.
📊
Key Findings & Data:The ninety-eight strains staphylococci (CNSs) and 24 S. aureus] isolated from various clinical samples were included the study which had been sent to microbiology laboratory.
💡
Conclusion & Impact:Consequently we think that quinupristin-dalfopristin combination may be an alternative option for treatment of resistant Gram-positive cocci infections like vancomycin
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Kinupristin-dalfopristin · metisilin · stafilokok

Abstract

The aim of the study is to investigate susceptibility of staphylococci strains isolated from various clinical samples to quinupristin-dalfopristin. The ninety-eight strains staphylococci (CNSs) and 24 S. aureus] isolated from various clinical samples were included the study which had been sent to microbiology laboratory. Staphylococci strains were identified by using conventional methods. Methicillin and quinupristin-dalfopristin susceptibility of staphylococci strains were performed by Kirby-Bauer’s disc diffusion method according to the Clinical and Laboratory Standards Institute criteria. Also, vancomycin susceptibility of strains was investigated by E-test method. Strain of S. aureus ATCC 25923 was used as the quality control strain. The fifty-three (72%) strains of the CNSs were defined as methicillinresistant CNS (MR-CNS), three (13%) strains of S. aureus was defined as methicillin-resistant S. aureus (MRSA). The eight (15%) strains of MR-CNS were found resistant to quinupristin-dalfopristin, one (5%) strain of MS-CNS were found resistant to quinupristin-dalfopristin. None of MSSA or MRSA strains were resistant to quinupristin-dalfopristin. All of the strains were found as susceptible to vancomycin. Strains of staphylococci were found susceptible to quinupristin-dalfopristin at high rates. Consequently we think that quinupristin-dalfopristin combination may be an alternative option for treatment of resistant Gram-positive cocci infections like vancomycin

Özet

Bu çalışmada, çeşitli klinik örneklerden izole edilen stafilokok suşlarında kinupristin-dalfopristin duyarlılık oranlarının araştırılması amaçlanmıştır. Çalışmaya, mikrobiyoloji laboratuvarına gönderilen çeşitli klinik örneklerden izole edilen 98 stafilokok suşu [74'ü koagülaz negatif stafilokok (KNS) ve 24'ü S. aureus] dahil edildi. Stafilokok suşları konvansiyonel yöntemler ile tanımlandı. Stafilokok suşlarının metisilin ve kinupristin-dalfopristin duyarlılığı Clinical and Laboratory Standards Institute (CLSI) önerileri doğrultusunda Kirby-Bauer disk difüzyon yöntemiyle çalışıldı. Ayrıca suşların vankomisin duyarlılığı E-test yöntemi ile araştırıldı. Çalışmada kalite kontrol suşu olarak S. aureus ATCC 25923 kullanıldı. İzole edilen KNS’lerin 53(% 72)’ü metisiline dirençli KNS (MR-KNS) ve S. aureus’ların ise 3(%13)’ü metisiline dirençli (MRSA) olarak tanımlandı. MRKNS’lerin 8(% 15)’i kinupristin-dalfopristine dirençli iken, metisiline duyarlı KNS'lerde (MS-KNS) kinupristindalfopristin direnci 1(%5) suşta tespit edildi. MSSA ve MRSA suşlarının hiçbirinde kinupristin-dalfopristin direnci tespit edilmedi. Suşların tamamının vankomisine duyarlı olduğu bulundu. Stafilokok suşlarının kinupristindalfopristine yüksek oranda duyarlı oldukları bulundu. Sonuç olarak vankomisin gibi kinupristin-dalfopristin kombinasyonun da özellikle dirençli Gram-pozitif kok enfeksiyonlarının tedavisinde alternatif olabileceğini düşünmekteyiz

🔖

Cite This Article

Yula, E., Özer, T. T., Deveci, O., Tekin, A., Yanık, K., Durmaz, S. (2012). Klinik Örneklerden İzole Edilen Staphylococcus Suşlarına Karşı Kinupristin-Dalfopristin, Metisilin ve Vankomisinin in vitro Etkinliğİ. Sağlık Bilimleri Dergisi, Cilt: 21 Sayı: 1, 45–49. https://ajindex.com/articles/1206479

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ünal S. New antimicrobial agents in the treat- ment of Gram-positive infections. Ankem Derg 2008; 22:297-306.
  2. Ulusoy S. Streptogramins (Quinupristin/ dalfopristin). Ankem Derg 2004; 18:174-177.
  3. Ermertcan Ş. The first parenteral strepto- gramin: Quinupristin/dalfopristin. İnfeksiyon Derg 2003; 3:369-373.
  4. Kang SL, Rybak MJ. In vitro bactericidal ac- tivity of Quinupristin/dalfopristin alone and in combination against resistant strains of En- terococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39:33-39.
  5. Allington DR, Rivey MP. Quinupristin/ dalfopristin: a therapeutic review. Clin Ther 2001; 23:24-44.
  6. Livermore DM. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 2000; 46:347- 350.
  7. Klastersky J. Role of Quinupristin/dalfopristin in the treatment of Gram-positive nasocomial infections in hematological or oncological patients. Cancer Treatment Reviews 2003; 29:431-440.
  8. John MA, Pletch C, Hussain Z. In vitro activity of Quinupristin/dalfopristin, linezolid, telithro- mycin and comparator antimicrobial agents 13 species of coagulase-negative staphylococci. J Antimicrob Chemother 2002; 50:933-938.
  9. Hwang SH, Kim MN, Pai CH, et al. In vitro activity of Quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea. Yonsei Med J 2000; 41:563-569.
  10. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36:473-481.
  11. Doğanay V, Kızırgil A. In vitro activities of Quinupristin/dalfopristin and eight other antim- icrobial agents against Gram-positive cocci. FÜ Sag Bil Tıp Derg 2007; 21:129-132.
  12. Doğruman-Al F, Akça G, Aykan B, et al. The susceptibility to Quinupristin/dalfopristin and Linesolid and resistance to Macrolide- Lincosamide-Streptogramin B in methicilline- resistant Staphylococcus aureus strains. Turk- ish Journal of Infection 2008; 22:153-163.
  13. Öksüz L, Gürler N. In vitro susceptibility of methicillin-resistant Staphylococci isolated from clinical samples to newer antibiotics. Ankem Derg 2009; 23:71-77.